Diabetes drug showdown: which one protects your heart?
NCT ID NCT06779929
Summary
This large study uses real-world insurance data to compare two weekly injectable diabetes medications, tirzepatide and dulaglutide. It aims to see which drug is better at preventing major heart problems like heart attacks and strokes in people who have both type 2 diabetes and established heart disease. The study is not testing a new drug but analyzing existing health records to understand real-world outcomes.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02120, United States
Conditions
Explore the condition pages connected to this study.